S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Fox Couldn't Air my #1 A.I. Pick - Get it Here. (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
Trudeau pledges Canada's support for Ukraine and punishment for Russia
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Fox Couldn't Air my #1 A.I. Pick - Get it Here. (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
Trudeau pledges Canada's support for Ukraine and punishment for Russia
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Fox Couldn't Air my #1 A.I. Pick - Get it Here. (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
Trudeau pledges Canada's support for Ukraine and punishment for Russia
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Fox Couldn't Air my #1 A.I. Pick - Get it Here. (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
Trudeau pledges Canada's support for Ukraine and punishment for Russia
NASDAQ:CDIO

Cardio Diagnostics (CDIO) Competitors

$0.38
-0.01 (-2.53%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.38
▼
$0.42
50-Day Range
$0.38
▼
$1.21
52-Week Range
$0.32
▼
$10.25
Volume
109,828 shs
Average Volume
250,585 shs
Market Capitalization
$4.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
ProfileAnalyst RatingsChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

CDIO vs. VRAX, NAVB, BMRA, MEDS, SQL, PXMD, SXTP, UPC, CLVR, and QLGN

Should you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include Virax Biolabs Group (VRAX), Navidea Biopharmaceuticals (NAVB), Biomerica (BMRA), TRxADE HEALTH (MEDS), SeqLL (SQL), PaxMedica (PXMD), 60 Degrees Pharmaceuticals (SXTP), Universe Pharmaceuticals (UPC), Clever Leaves (CLVR), and Qualigen Therapeutics (QLGN). These companies are all part of the "medical" sector.

Cardio Diagnostics vs.

Virax Biolabs Group (NASDAQ:VRAX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Cardio Diagnostics has lower revenue, but higher earnings than Virax Biolabs Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virax Biolabs Group$10K549.38-$5.46MN/AN/A
Cardio DiagnosticsN/AN/A-$4.66MN/AN/A

Cardio Diagnostics' return on equity of 0.00% beat Virax Biolabs Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Virax Biolabs GroupN/A N/A N/A
Cardio Diagnostics N/A -334.08%-39.31%

0.4% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 3.5% of Cardio Diagnostics shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 45.9% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Virax Biolabs Group has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of -1.93, meaning that its stock price is 293% less volatile than the S&P 500.

In the previous week, Virax Biolabs Group had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Virax Biolabs Group and 0 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.77 beat Virax Biolabs Group's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company Overall Sentiment
Virax Biolabs Group Positive
Cardio Diagnostics Neutral

Cardio Diagnostics received 1 more outperform votes than Virax Biolabs Group when rated by MarketBeat users.

CompanyUnderperformOutperform
Virax Biolabs GroupN/AN/A
Cardio DiagnosticsOutperform Votes
1
50.00%
Underperform Votes
1
50.00%

Cardio Diagnostics has a consensus target price of $8.00, indicating a potential upside of 1,977.92%. Given Virax Biolabs Group's higher probable upside, analysts plainly believe Cardio Diagnostics is more favorable than Virax Biolabs Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Cardio Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Virax Biolabs Group and Cardio Diagnostics tied by winning 6 of the 12 factors compared between the two stocks.


Get Cardio Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CDIO vs. The Competition

Export to Excel
MetricCardio DiagnosticsDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$4.54M$2.45B$4.49B$6.27B
Dividend YieldN/A0.70%2.58%6.51%
P/E RatioN/A20.37111.7711.93
Price / SalesN/A54.662,859.2565.45
Price / CashN/A5,078.0492.75100.49
Price / Book0.865.633.764.83
Net Income-$4.66M$40.25M$122.26M$186.05M
7 Day Performance-21.43%-7.15%-2.59%-3.10%
1 Month Performance-33.61%-9.22%-3.58%-5.68%
1 Year PerformanceN/A-22.93%9.52%5.50%

Cardio Diagnostics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
1.7288 of 5 stars		$0.36
flat		N/A-89.2%$5.54M$10,000.000.0011News Coverage
Gap Down
NAVB
Navidea Biopharmaceuticals
0 of 5 stars		$0.10
+11.2%		N/A-59.8%$9.24M$8,126.00-0.3411Gap Up
High Trading Volume
BMRA
Biomerica
0 of 5 stars		$1.11
+0.9%		N/A-70.8%$18.67M$5.34M-2.2262Positive News
MEDS
TRxADE HEALTH
1.7469 of 5 stars		$7.48
+1.1%		$26.25
+250.9%		-61.3%$5.04M$9.43M-1.1833Gap Up
SQL
SeqLL
0 of 5 stars		$14.37
-7.9%		N/A-53.1%$5.03M$80,000.00-0.887Gap Down
PXMD
PaxMedica
0 of 5 stars		$0.31
-3.2%		N/A-87.3%$5.03MN/A-0.153Gap Down
SXTP
60 Degrees Pharmaceuticals
0 of 5 stars		$0.86
-25.2%		N/AN/A$4.99M$510,000.000.002Positive News
UPC
Universe Pharmaceuticals
0 of 5 stars		$1.36
-2.2%		N/A-69.1%$4.94M$40.14M0.00224
CLVR
Clever Leaves
1.9938 of 5 stars		$3.39
-6.9%		$68.25
+1,913.3%		-83.0%$5.15M$17.80M-0.09400
QLGN
Qualigen Therapeutics
1.6875 of 5 stars		$0.97
-5.8%		$4.00
+312.3%		+263.2%$4.90M$4.98M0.0031Positive News
Gap Up

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:CDIO) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -